Earnings Call · Q1 FY2022·2022-05-11

Q1 22EPS -4.17%·Rev n/aQ4 21EPS -75.00%·Rev n/aQ3 21EPS -5.41%·Rev n/aQ2 21EPS -36.67%·Rev n/a⚠ consensus missing

Xeris Biopharma Holdings, Inc. XERS

Allison Wey — Investor Relations or Corporate Communications

Paul Edick — Chief Executive Officer (CEO)

Steve Pieper — Chief Financial Officer (CFO)

−8.4%1d on move date−6.8% vs SPY3d−4.5%5d+35.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more XERS calls or request research access.

More XERS calls Browse calls Request research access